Journal
ALZHEIMERS & DEMENTIA
Volume 14, Issue 4, Pages 563-575Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2018.03.002
Keywords
Alzheimer's disease; Amyloid; Tau; Neurodegeneration; Clinical trials; Biomarkers
Categories
Funding
- VA [1043379, 1I01CX000409-01, 549456, 2I01CX000409-05A1] Funding Source: Federal RePORTER
- Intramural NIH HHS [Z99 AG999999] Funding Source: Medline
- NIA NIH HHS [P30 AG028383] Funding Source: Medline
- CSRD VA [I01 CX000409] Funding Source: Medline
Ask authors/readers for more resources
The Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the A, T, N System (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
